A Single Dose Study of the Pharmacodynamics, Tolerability, and Pharmacokinetics of GAL-054

Completed

• Conditions: Breath disorders; 10038716

• Registration Number: NL-OMON37672
• Lead Sponsor: Galleon Pharmaceuticals, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 36

Inclusion Criteria

Healthy volunteer
18-45 years

Exclusion Criteria

Clinical significant abnormalities

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The pharmacodynamic effects of GAL-054 in comparison to doxapram in healthy<br /><br>subjects </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Tolerability and pharmacokinetics</p><br>